| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 02/13/2001 | CA2161903C Polymer composition, absorbent material composition, their production and use |
| 02/13/2001 | CA2161902C Polymer composition, absorbent material composition, their production and use |
| 02/13/2001 | CA2146637C Pharmaceutical compositions and methods for treating cold symptoms |
| 02/13/2001 | CA2139358C Human growth hormone aqueous formulation |
| 02/13/2001 | CA2059288C Fluorine and phosphorous-containing amphiphilic molecules with surfactant properties |
| 02/13/2001 | CA2022104C Supercritical fluid and near critical gas extraction of organic solvents from formed articles |
| 02/13/2001 | CA2021501C Topical pharmaceutical compositions |
| 02/13/2001 | CA2016505C Water soluble high molecular polymerized drug preparation |
| 02/13/2001 | CA2012876C Use of 5-methyltetrahydrofolic acid and 5-formyltetrahydrofolic acid in the treatment of organic mental disturbances |
| 02/09/2001 | CA2315594A1 Process for the preparation of aqueous formulations for ophthalmic use |
| 02/08/2001 | WO2001009379A1 Antisense modulation of pepck-mitochondrial expression |
| 02/08/2001 | WO2001009342A1 Microencapsulated nitric oxide synthase source |
| 02/08/2001 | WO2001009198A1 Temperature sensitive polymers |
| 02/08/2001 | WO2001009195A1 Cyclodextrins monosubstituted to persubstituted by fluoroalkyl groups, preparation and use thereof |
| 02/08/2001 | WO2001009156A1 HIGH AFFINITY TGFη NUCLEIC ACID LIGANDS AND INHIBITORS |
| 02/08/2001 | WO2001009151A1 Process for preparing a charcoal-gm1 complex |
| 02/08/2001 | WO2001009139A1 Aromatic esters of camptothecins and methods to treat cancers |
| 02/08/2001 | WO2001009000A1 A device for spray dispensing a composition for topical application comprising vitamin e and essential fatty acids |
| 02/08/2001 | WO2001008728A1 Portable pain relieving device |
| 02/08/2001 | WO2001008714A1 Cartilage or bone matrix as a nucleic acid delivery vehicle |
| 02/08/2001 | WO2001008708A2 Enhanced delivery via serpin enzyme complex receptor ligands |
| 02/08/2001 | WO2001008688A2 Beta-carboline drug products |
| 02/08/2001 | WO2001008687A1 Beta-carboline pharmaceutical compositions |
| 02/08/2001 | WO2001008686A1 Beta-carboline pharmaceutical compositions |
| 02/08/2001 | WO2001008680A1 Preparations for reducing oxygen consumption during physical efforts |
| 02/08/2001 | WO2001008671A2 Method and composition for prophylaxis and treatment of symptoms associated with cold and influenza-like illnesses |
| 02/08/2001 | WO2001008666A1 Multi-component pharmaceutical dosage form |
| 02/08/2001 | WO2001008665A1 Paracetamol controlled-release compositions |
| 02/08/2001 | WO2001008664A1 Acetylsalicylic acid controlled-release compositions |
| 02/08/2001 | WO2001008663A2 Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
| 02/08/2001 | WO2001008661A2 Opioid sustained-released formulation |
| 02/08/2001 | WO2001008659A1 Pharmaceutical compositions for topical application to treat erectile dysfunction |
| 02/08/2001 | WO2001008641A2 Personal care articles |
| 02/08/2001 | WO2001008636A2 Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein |
| 02/08/2001 | WO2001008632A2 Colloidal composition for esthetic correction |
| 02/08/2001 | WO2001008609A1 Method and article to induce hematopoietic expansion |
| 02/08/2001 | WO2001008505A2 Methods for suppressing appetite and enhancing exercise and recovery |
| 02/08/2001 | WO2001008496A1 Antiparasitic formulation |
| 02/08/2001 | WO2001008495A1 Rotavirus vaccine formulations |
| 02/08/2001 | WO2000072828B1 A method of tabletting dose units of active agents |
| 02/08/2001 | WO2000069894A3 Novel indications of mannan-binding lectin (mbl) in the treatment of immunocompromised individuals |
| 02/08/2001 | WO2000069520A3 Use of topical azathioprine to treat inflammatory bowel disorders |
| 02/08/2001 | WO2000069456A3 Adjuvant combination formulations |
| 02/08/2001 | WO2000069449A3 Conditioned cell culture medium compositions and methods of use |
| 02/08/2001 | WO2000066206A3 Compositions for aerosolization and inhalation |
| 02/08/2001 | WO2000065024A3 Hyperbranched polymeric micelles for encapsulation and delivery of hydrophobic molecules |
| 02/08/2001 | WO2000059851A8 Derivatives of venlafaxine and methods of preparing and using the same |
| 02/08/2001 | WO2000057919A3 Lipid-based artificial particles inducing cell-mediated immunity |
| 02/08/2001 | WO2000054758A3 Method for delivering benzidine prostaglandins by inhalation |
| 02/08/2001 | WO2000007627A8 Topical delivery systems for active agents |
| 02/08/2001 | DE19937116A1 Moxifloxacin Kochsalzformulierung Moxifloxacin saline formulation |
| 02/08/2001 | DE19937115A1 Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon An aqueous pharmaceutical formulation of moxifloxacin or salts thereof |
| 02/08/2001 | DE19936545A1 Nasal pharmaceutical composition, useful e.g. for delivering corticosteroids, comprises at least one water-soluble active ingredient and a neutral oil e.g. a medium-chain fatty acid triglyceride or propylene glycol ester |
| 02/08/2001 | DE19936543A1 Composition for intranasal administration of water-insoluble drugs, e.g. scopolamine, budesonide or diazepam, comprising a solution of the water-insoluble or sparingly water-soluble drug in a neutral oil e.g. a triglyceride |
| 02/08/2001 | CA2391348A1 Enhanced delivery via serpin enzyme complex receptor |
| 02/08/2001 | CA2380837A1 High affinity tgf.beta. nucleic acid ligands and inhibitors |
| 02/08/2001 | CA2380787A1 Microencapsulated nitric oxide synthase source |
| 02/08/2001 | CA2379987A1 Opioid sustained-released formulation |
| 02/08/2001 | CA2379703A1 Method and composition for prophylaxis and treatment of symptoms associated with cold and influenza-like illnesses |
| 02/08/2001 | CA2379663A1 Cartilage or bone matrix as a nucleic acid delivery vehicle |
| 02/08/2001 | CA2379660A1 Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
| 02/08/2001 | CA2379343A1 Personal care articles |
| 02/08/2001 | CA2378864A1 Rotavirus vaccine formulations |
| 02/08/2001 | CA2378155A1 Colloidal composition for esthetic correction |
| 02/07/2001 | EP1074625A2 DNA vaccine against feline immunodeficiency virus |
| 02/07/2001 | EP1074620A1 Monomeric protein of the TGF-beta family |
| 02/07/2001 | EP1074592A1 Process for preparing beadlets containing fat-soluble substances |
| 02/07/2001 | EP1074263A2 Pharmaceutical compositions of macrolides or cyclosporine with a polyethoylate saturated hydroxy-fatty acid |
| 02/07/2001 | EP1074262A1 Laminaria algae extract, method of preparation and cosmetic or pharmaceutical compositions containing the same |
| 02/07/2001 | EP1074261A1 Iodophor compositions for preventing mastitis |
| 02/07/2001 | EP1074255A1 Medicinal compositions |
| 02/07/2001 | EP1074253A1 Oral preparations containing forskolin derivatives and process for producing medicinal preparations |
| 02/07/2001 | EP1074251A1 Adhesive preparations |
| 02/07/2001 | EP1074250A1 Sugar coated tablets |
| 02/07/2001 | EP1074249A1 A pharmaceutical tablet system for releasing at least one active substance during a release period subsequent to a no-release period |
| 02/07/2001 | EP1074248A1 Delivery system for biological material |
| 02/07/2001 | EP1074185A1 Incorporation of cholesterol lowering agents into confectionery dosage forms |
| 02/07/2001 | EP1073693A1 Coprecipitation of cellulose esters with functional additives and compositions thus obtainable |
| 02/07/2001 | EP1073682A1 Heparanase specific molecular probes and their use in research and medical applications |
| 02/07/2001 | EP1073594A1 Metered dose valve for pharmaceutical aerosol |
| 02/07/2001 | EP1073474A1 Improvements in or relating to contrast agents |
| 02/07/2001 | EP1073470A1 Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients |
| 02/07/2001 | EP1073469A1 Stable mitoxantron solutions |
| 02/07/2001 | EP1073468A1 Use of an adhesive composition over a bioactive polymerization initiator or accelerator |
| 02/07/2001 | EP1073467A2 Cosolvent formulations |
| 02/07/2001 | EP1073466A1 Solution containing nicotine |
| 02/07/2001 | EP1073451A2 Method for treating ischemia |
| 02/07/2001 | EP1073439A1 Pharmaceutical composition |
| 02/07/2001 | EP1073438A1 8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDYLIDENE)-5H-BENZO 5,6]CYCLOHEPTA 1,2-b]PYRIDINE ORAL COMPOSITIONS |
| 02/07/2001 | EP1073429A1 Aerosol formulations of salmeterol xinafoate |
| 02/07/2001 | EP1073427A1 Periadventitial delivery device |
| 02/07/2001 | EP1073426A1 Pharmaceutical cyclosporin formulation with improved biopharmaceutical properties, improved physical quality and greater stability, and method for producing said formulation |
| 02/07/2001 | EP1073425A1 Fibrinogen coated droplets of liquid hydrophobic phases |
| 02/07/2001 | EP1073424A1 Pellets having a core coated with a lipid lowering agent and a polymer |
| 02/07/2001 | EP1073423A1 Coated donut-shaped tablets with long-term parabolic and zero-order release kinetics |
| 02/07/2001 | EP1073422A1 Matrices formed of polymer and hydrophobic compounds for use in drug delivery |
| 02/07/2001 | EP1073421A1 Stabilized protein crystals, formulations containing them and methods of making them |
| 02/07/2001 | EP1073419A2 Sustained-release composition including amorphous polymer |
| 02/07/2001 | EP1073418A1 Aqueous composition comprising active ingredients for the de-pigmentation of the skin |
| 02/07/2001 | EP1073417A1 Pharmaceutical aerosol formulation |